We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+18.12%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$344M
AUM Growth
+$122M
Cap. Flow
+$79.6M
Cap. Flow %
23.16%
Top 10 Hldgs %
70.07%
Holding
43
New
16
Increased
6
Reduced
4
Closed
7

Top Buys

1
INCY icon
Incyte
INCY
+$20.2M
2
AGEN
Agenus
AGEN
+$14.8M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.5M
4
CLDX icon
Celldex Therapeutics
CLDX
+$12.5M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$8.44M

Top Sells

1
DYAX
DYAX CORPORATION
DYAX
+$27.2M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$16.1M
3
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$3M
4
ASMB icon
Assembly Biosciences
ASMB
+$2.7M
5
ADVM
Adverum Biotechnologies
ADVM
+$2.08M

Sector Composition

1 Healthcare 72.08%
2 Financials 0%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$37.8B
$49.3M 14.34%
411,016
+55,621
+16% +$6.65M
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$2.31B
$33.8M 9.83%
2,261,361
– –
KITE
3
DELISTED
Kite Pharma, Inc.
KITE
$24.4M 7.1%
400,000
+24,377
+6% +$1.39M
ACHN
4
DELISTED
Achillion Pharmaceuticals
ACHN
$22.3M 6.49%
2,515,433
+892,800
+55% +$8.44M
INCY icon
5
Incyte
INCY
$23.3B
$20.3M 5.92%
+195,000
New +$20.2M
ARWR icon
6
Arrowhead Research
ARWR
$10.1B
$18.3M 5.33%
2,560,000
+150,000
+6% +$1.03M
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$17.9M 5.2%
1,279,886
+288,905
+29% +$5.3M
AGEN
8
Agenus
AGEN
$208M
$17.7M 5.16%
+104,596
New +$14.8M
BLUE
9
DELISTED
bluebird bio
BLUE
$17.7M 5.15%
8,106
+386
+5% +$786K
DYAX
10
DELISTED
DYAX CORPORATION
DYAX
$14.8M 4.31%
559,141
-1,025,957
-65% -$27.2M
FPRX
11
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$13.9M 4.05%
+560,437
New +$12.5M
CLDX icon
12
Celldex Therapeutics
CLDX
$2.78B
$11.9M 3.46%
+31,437
New +$12.5M
GYRE icon
13
Gyre Therapeutics
GYRE
$716M
$7.44M 2.16%
3,385
– –
LJPC
14
DELISTED
La Jolla Pharmaceutical Company
LJPC
$6.95M 2.02%
283,700
-780,547
-73% -$16.1M
BMY icon
15
Bristol-Myers Squibb
BMY
$124B
$6.49M 1.89%
+97,454
New +$6.42M
BMY icon
16
CALL
Bristol-Myers Squibb
BMY
$124B
– –
0
– –
SSRG
17
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
$6.11M 1.78%
+700,851
New +$5.78M
CORI
18
DELISTED
Corium International, Inc.
CORI
$4.86M 1.41%
+355,007
New +$4.01M
LUMO
19
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.43M 1.29%
+11,111
New +$4.72M
TLT icon
20
iShares 20+ Year Treasury Bond ETF
TLT
$41.9B
$3.88M 1.13%
+33,000
New +$4.05M
USO icon
21
United States Oil Fund
USO
$2.45B
$3.28M 0.95%
+20,625
New +$3.28M
LENS
22
DELISTED
Presbia PLC Ordinary Shares
LENS
$2.88M 0.84%
350,000
– –
IVTY
23
DELISTED
Invuity, Inc
IVTY
$2.33M 0.68%
+165,000
New +$2.4M
LPCN icon
24
Lipocine
LPCN
$18.9M
$1.8M 0.52%
12,314
– –
CYTR
25
DELISTED
CytRx Corp
CYTR
$1.66M 0.48%
74,452
-19,517
-21% -$489K
1
2

Similar funds

BEI
Benjamin Edwards Inc Clayton, Missouri $10.1B AUM 14.03% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return

RTW Investments's Q2 2015 Portfolio in Review

As of Q2 2015, RTW Investments held 43 positions worth $344M, up 55% from $222M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

RTW Investments deployed $79.6M of net new capital in Q2 2015, opening 16 new positions and adding to 6 existing holdings. Its largest new stake was Incyte: 195,000 shares worth $20.3M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 66% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was DYAX CORPORATION, an estimated $27.2M trimmed.

  • RTW Investments's largest Q2 2015 buy was Incyte: 195,000 shares worth $20.3M.
  • RTW Investments added most to Achillion Pharmaceuticals in Q2 2015, an estimated $8.44M increase.
  • RTW Investments's biggest Q2 2015 reduction was DYAX CORPORATION, cutting an estimated $27.2M.
  • RTW Investments fully exited ZS PHARMA INC COMS TK (DE) in Q2 2015, selling an estimated $3M.
  • RTW Investments's ten largest holdings make up 70% of its $344M portfolio in Q2 2015.
  • RTW Investments opened 16 new positions and closed 7 in Q2 2015.
  • RTW Investments's portfolio value rose 55% quarter-over-quarter to $344M.

Based on RTW Investments's 13F filing for Q2 2015, filed 14 Aug 2015.